Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576145 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT02576145 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 11 participants.
The verdict
NCT02576145, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response. The anticipated time on study treatment is 1 day, and the target sample size is 82 individuals.
Interventions
- DRUG Daclizumab
- BIOLOGICAL DT
- BIOLOGICAL KLH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576145
The ClinicalTrials.gov registry entry for NCT02576145 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Daclizumab is the first listed.
NCT02576145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576145 about?
NCT02576145 is a clinical study titled "A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)". This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response. The anticipated time on study treatment is 1 day, and the target sample size is 82 individuals.
What is the current status of trial NCT02576145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2003-04. Estimated completion is 2006-01.
What interventions are being tested in trial NCT02576145?
The interventions under investigation include: Daclizumab (DRUG), DT (BIOLOGICAL), KLH (BIOLOGICAL).
Who is sponsoring clinical trial NCT02576145?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.